CN115975870A - Enterococcus faecium with porcine epidemic diarrhea virus resisting function and application thereof - Google Patents
Enterococcus faecium with porcine epidemic diarrhea virus resisting function and application thereof Download PDFInfo
- Publication number
- CN115975870A CN115975870A CN202211474092.8A CN202211474092A CN115975870A CN 115975870 A CN115975870 A CN 115975870A CN 202211474092 A CN202211474092 A CN 202211474092A CN 115975870 A CN115975870 A CN 115975870A
- Authority
- CN
- China
- Prior art keywords
- enterococcus faecium
- efa5
- epidemic diarrhea
- porcine epidemic
- diarrhea virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000194031 Enterococcus faecium Species 0.000 title claims abstract description 71
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 title claims abstract description 53
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000003674 animal food additive Substances 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 29
- 238000000855 fermentation Methods 0.000 claims description 28
- 230000004151 fermentation Effects 0.000 claims description 28
- 241000700605 Viruses Species 0.000 claims description 27
- 206010012735 Diarrhoea Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000003608 fece Anatomy 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000009629 microbiological culture Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 13
- 239000006041 probiotic Substances 0.000 abstract description 13
- 230000000529 probiotic effect Effects 0.000 abstract description 13
- 235000018291 probiotics Nutrition 0.000 abstract description 13
- 230000012010 growth Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 47
- 239000006228 supernatant Substances 0.000 description 30
- 239000001963 growth medium Substances 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 238000012258 culturing Methods 0.000 description 13
- 210000003501 vero cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000002356 single layer Substances 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000003833 bile salt Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 206010051511 Viral diarrhoea Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 108020005075 5S Ribosomal RNA Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 241001367898 Enterococcus faecium NBRC 100486 Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012499 inoculation medium Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an Enterococcus faecium (Enterococcus faecium) EFA5 with a function of resisting porcine epidemic diarrhea virus, wherein the preservation number is as follows: GDMCC NO.62904, deposited in the Guangdong province culture Collection of microorganisms at the institute of microbiology, guangdong province academy of sciences, guangzhou, guangdong province. Research shows that the strain has obvious probiotic characteristics, rapid growth and strong acid production capacity, and can be colonized in pig intestines. In addition, the compound has strong capability of resisting porcine epidemic diarrhea virus. The strain can be used as probiotic bacteria for preparing feed or feed additives, and has a wide application scene in preparing medicaments for resisting porcine epidemic diarrhea viruses.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to enterococcus faecium with a porcine epidemic diarrhea virus resisting function and application thereof.
Background
Intestinal diseases are a common problem in modern pig farms, but diarrhea diseases are relatively easy to occur in piglet stages and comprise bacterial diarrhea, viral diarrhea, nutritional diarrhea and diarrhea caused by parasites, wherein the viral diarrhea has high incidence rate, rapid transmission, wide transmission range, high death rate and unobvious treatment effect, the prevention is mainly performed, in particular to Porcine Epidemic Diarrhea Virus (PEDV) which continuously erupts in 2010 till now, the epidemic diarrhea is acute highly infectious diseases and mainly presents clinical symptoms such as diarrhea, vomiting, dehydration and the like, the death rate of some pig farms in part of large-scale pig farms is high and even can reach over 80%, the death rate of some pig farms is an important cause of enteritis and death of newborn piglets, and the economic loss is caused to the breeding industry.
The prevention effect is better than the treatment effect for diseases, especially viral diseases, but PEDV is not exceptional, and PEDV has strict cell tropism and host specificity. However, due to viral genetic variation, effective vaccine protection is affected; antiviral drugs generally have severe toxic side effects and are limited in use amount and effect. Therefore, there is a continuing need for effective methods of controlling viral diseases, and probiotics are receiving widespread attention for their non-toxic, non-drug resistant, residue-free, antibacterial, antiviral, growth-promoting, green and safe advantages.
Enterococcus urinarius has obvious probiotic characteristics, and most strains are safe and reliable, so the enterococcus urinarius becomes one of the probiotic strains which are published in 1989 and can be directly fed by words, and is also a probiotic strain which is allowed to be used in related documents of feed additive variety catalog of Ministry of agriculture in China, and a plurality of pharmaceutical companies and enterprises prepare the probiotic preparation for adjusting the intestinal microecology of human or animals. Enterococcus faecium can regulate the balance of intestinal flora, reduce the infection of pathogenic bacteria in the intestinal tract, treat diarrhea and enteritis, and enhance the immune function of a host, and can generate organic acid, hydrogen peroxide, bacteriocin and the like through normal metabolism so as to inhibit and kill pathogenic bacteria and viruses. Related researches show that the enterococcus faecium can inhibit the replication of the porcine transmissible gastroenteritis virus and the porcine influenza A virus, but no report is found on the porcine epidemic diarrhea virus.
Disclosure of Invention
Based on the strain, the enterococcus faecium with the function of resisting the porcine epidemic diarrhea virus and the application thereof are provided, and the strain can be used for preparing feeds, feed additives and medicines for preventing PEDV, so that a new direction is provided for preventing and treating the PEDV.
In a first aspect of the present invention, there is provided an Enterococcus faecium (Enterococcus faecium) EFA5 strain having a function of resisting porcine epidemic diarrhea virus, wherein the collection number is: GDMCC NO.62904 is deposited at the Guangdong province culture Collection of microorganisms at 2022, 10 months and 19 days, and the deposit is the institute of microorganisms of Guangdong province academy of sciences, guangzhou, guangdong province.
The 16S rRNA gene sequence of the Enterococcus faecium (Enterococcus faecium) EFA5 is shown in SEQ ID NO. 1. The strain has the following microbiological characteristics: bacterial colonies of the strain EFA5 on a culture medium are milky white, the center of the bacterial colonies is smooth and convex, and the edge of the bacterial colonies is rough; the strain is in a short rod shape under a lens, gram stain is positive, and no spore exists; the growth is rapid, and the stable period can be reached after the growth is carried out for 18 hours on the culture medium; has stronger acid production capacity, and the pH value of the culture medium is close to 4.0 from 5.4 within 20 hours; has good acid resistance and bile salt resistance; has stronger adhesion capability to the epithelial cells of the small intestine of the pig.
The enterococcus faecium EFA5 is obtained by separating feces of healthy Luchuan sows and weaned piglets.
The enterococcus faecium EFA5 has an inhibition effect on porcine epidemic diarrhea viruses, the inhibition rate of the fermented supernatant of the enterococcus faecium EFA5 on PEDV is indirectly detected by a CCK8 method, the inhibition rate of the fermented supernatant of the enterococcus faecium EFA5 on the PEDV is found to be very strong at a cell level, and the inhibition rate of the fermented supernatant with 1/4 dilution on the PEDV is about 0.6; TCID of the experimental group to which the fermentation supernatant was added was found by examining the influence of the enterococcus faecium EFA5 fermentation supernatant on the PEDV titer 50 Is 10 -3.50 0.1ml of TCID of control without addition of fermentation supernatant 50 Is 10 -4.33 0.1ml; by determining the effect of the PEDV fermentation supernatant on the copy number of the virus M gene, after 24 hours of culture, the copy number of the virus M gene of the probiotic fermentation supernatant treatment group was found to be significantly lower than that of the control group.
In a second aspect of the invention there is provided a feed or feed additive comprising enterococcus faecium EFA5 or a fermentation product thereof.
In a third aspect of the invention, the application of enterococcus faecium EFA5 in the preparation of a medicament for resisting porcine epidemic diarrhea virus is provided.
In some of these embodiments, the medicament contains enterococcus faecium EFA5 and/or a fermentation product thereof.
In some of these embodiments, the pharmaceutical dosage form is a tablet, capsule, powder, pill, granule, or solution.
In some of these embodiments, the medicament comprises enterococcus faecium EFA5 and a pharmaceutically acceptable excipient.
Compared with the prior art, the invention has the following advantages:
the enterococcus faecium EFA5 provided by the invention has obvious probiotic characteristics, can grow rapidly, has strong acid production capacity, can be colonized in the porcine intestinal tract, and experimental determination shows that the enterococcus faecium EFA5 screened by the invention can effectively inhibit the replication of Porcine Epidemic Diarrhea Virus (PEDV) and has strong antiviral capacity. The enterococcus faecium with the function of resisting the porcine epidemic diarrhea virus disclosed by the invention can be used as a probiotic for preparing feed or feed additives, and has a wide application scene in preparing medicaments for resisting the porcine epidemic diarrhea virus.
Drawings
FIG. 1 is a morphological diagram of an enterococcus faecium EFA5 colony;
FIG. 2 is a gram stain microscopic image of enterococcus faecium EFA5 under a 100-fold oil microscope;
FIG. 3 is a diagram of the genetic evolution analysis of enterococcus faecium EFA 5S rRNA;
FIG. 4 is a graph of the growth of enterococcus faecium EFA 5;
FIG. 5 is a graph of acid production by enterococcus faecium EFA 5;
FIG. 6 is a graph of the results of an acid and bile salt tolerance assay for enterococcus faecium EFA 5;
FIG. 7 is a graph showing the adhesion of enterococcus faecium EFA5 to IPEC-J2 cells;
FIG. 8 is a normal morphology map of vero cells;
FIG. 9 is a graph showing the results of PEDV infection of vero cells to produce cytopathic effects;
FIG. 10 is a graph showing the results of the cytotoxicity assay of enterococcus faecium EFA5 fermentation supernatant;
FIG. 11 is a graph showing the results of measuring the PEDV inhibition ratio of the E.faecium EFA5 fermentation supernatant;
FIG. 12 is a graph showing the results of measurement of the effect of enterococcus faecium EFA5 fermentation supernatant on PEDV titer;
FIG. 13 is a graph showing the results of measurement of the influence of the supernatant from the enterococcus faecium EFA5 fermentation on the copy number of the PEDV M gene.
Detailed Description
To facilitate an understanding of the invention, the invention will now be described more fully with reference to the accompanying drawings. Preferred embodiments of the present invention are shown in the drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
In the present invention, "first aspect", "second aspect", "third aspect", "fourth aspect" and the like are used for descriptive purposes only and are not to be construed as indicating or implying a relative importance or quantity, nor as implying an importance or quantity indicating the technical feature indicated. Also, "first," "second," "third," "fourth," etc. are used for non-exhaustive enumeration of description purposes only and should not be construed as a closed limitation to the number.
As used herein, the term "and/or", "and/or" includes any one of two or more of the associated listed items, as well as any and all combinations of the associated listed items, including any two of the associated listed items, any more of the associated listed items, or all combinations of the associated listed items.
In the present invention, the technical features described in the open type include a closed technical solution including the listed features, and also include an open technical solution including the listed features.
In the following examples of the invention, the experimental materials and reagent sources used are as follows:
the porcine enterococcus faecium (Limosilactibacillus reuteri) EFA5 is preserved in a strain preservation center with the preservation number as follows: GDMCC NO.62904.
Porcine small intestinal epithelial (IPEC-J2) cells and african green monkey kidney (Vero) cells were stored by the laboratory.
The PEDV-JS2013 strain was presented by the Shanghai veterinary institute.
Other such agents or materials, unless otherwise specified, are commercially available.
Example 1 isolation and identification of enterococcus faecium
1.1 Strain isolation
Collecting feces of healthy Luchuan sow and weaned piglet in certain pig farm of Guangxi Guigang Yangxiang Bingxiang Bingquan, taking 1g feces sample, adding 99ml sterile normal saline in sterile environment, shaking up fully, diluting feces sample in gradient of 10 -3 、10 -4 、10 -5 、10 -6 . MRS medium (Kyoto loop Kai Biotechnology Co., ltd.; 027315) was sterilized and then inverted, after it was solidified, 100. Mu.L of each sample dilution with different gradients was applied to the plate, numbered and recorded, and then placed in an incubator at 37 ℃ for anaerobic culture for 48 hours. And (3) selecting a colony with a typical shape on a plate to an MRS culture medium for streak purification, selecting a single colony after purification, inoculating the single colony into the MRS liquid culture medium, carrying out anaerobic culture at 37 ℃ for 48h, and storing 25% glycerol in a ultralow temperature refrigerator at-80 ℃ to obtain the strain EFA5.
1.2 identification of the Strain
And (3) carrying out gram staining on the separated strains, and selecting the strains which are rod-shaped or short rod-shaped under the microscope, gram-positive and spore-free for further identification. Bacterial colonies of the strain EFA5 on an MRS culture medium are milky white, the center of the bacterial colonies is smooth and convex, the edge of the bacterial colonies is rough, and the morphology of the bacterial colonies is shown in figure 1; the strain is short rod-shaped under the lens, gram-positive, has no spore, and the thallus morphology is shown in figure 2.
The bacterial strain EFA5 was subjected to genomic DNA extraction using a bacterial DNA extraction kit (Servicebio, china), followed by PCR amplification of the 16S gene using Ex Taq DNA Polymerase kit (TaKaRa, china). 16S rRNA gene amplification was performed on the strain using 27F (5 'AGAGTTTGATCCTGGCTCAG 3') and 1492R (5 'TACGGTTACCTTGTTGACTT 3') universal primers. The amplification conditions were: pre-denaturation at 95 ℃ for 5min; 35 cycles of 95 ℃ 30s,56 ℃ 30s,72 ℃ 1min30s, and 72 ℃ annealing and extending for 10min. After pipetting 5. Mu.L of the PCR product and detecting the product by 1% (w/v) agarose gel electrophoresis, the remaining PCR product was used as a sample and sent to Shanghai Producer for sequencing. The sequence was aligned to the NCBI database (https:// blast. NCBI. Nlm. Nih. Gov) and phylogenetic trees were established using MEGA 5.1 software. As shown in FIG. 3, the established phylogenetic tree shows that the strain has the closest homology with Enterococcus faecium ATCC 19434 (ID: NR _ 115764.1), enterococcus faecium NBRC 100486 (ID: NR _ 113904.1) and 16Sr RNA of Enterococcus faecium DSM 20477 (ID: NR _ 114742.1) in GenBank of NCBI, and the strain is determined to be Enterococcus faecium and named as Enterococcus faecium EFA5. And Enterococcus faecium (Enterococcus faecium) EFA5 is preserved in No. 10/25 in 2022 in Guangdong province microorganism culture collection center with the preservation number of GDMCC NO.62904, the survival state is survival, the preservation address is Microbiol institute of Guangdong academy of sciences in Guangdong province, guangzhou, the postal code is 510075, and the contact telephone is 020-87137633.
The sequencing result of the 16S rRNA gene of the EFA5 strain is shown in SEQ ID NO. 1:
ACCGGAGCTTGCTCCACCGGAAAAAGAGGAGTGGCGAACGGGTGAGTAACACGTGGGTAACCTGCCCATCAGAAGGGGATAACACTTGGAAACAGGTGCTAATACCGTATAACAATCAAAACCGCATGGTTTTGATTTGAAAGGCGCTTTCGGGTGTCGCTGATGGATGGACCCGCGGTGCATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCCACGATGCATAGCCGACCTGAGAGGGTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCGGCAATGGACGAAAGTCTGACCGAGCAACGCCGCGTGAGTGAAGAAGGTTTTCGGATCGTAAAACTCTGTTGTTAGAGAAGAACAAGGATGAGAGTAACTGTTCATCCCTTGACGGTATCTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTCTTAAGTCTGATGTGAAAGCCCCCGGCTCAACCGGGGAGGGTCATTGGAAACTGGGAGACTTGAGTGCAGAAGAGGAGAGTGGAATTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAGGAACACCAGTGGCGAAGGCGGCTCTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTGGAGGGTTTCCGCCCTTCAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTTGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCCTTTGACCACTTTAGAGATAGAGCTTCCCCTTCGGGGGCAAAGTGACAGGTGGTGCATGGTTGTTGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTGTTAGTTGCCATCATTCAGTTGGGCACTTTAGCAAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGGAAGTACAACGAGTTGCGAAGTCGCGAGGCTAAGCTAATCTTTTAAAGCTTCTTTCAGTTCGGATTGCAGGCTGCAACTCGCCTGCATGAAGCCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACCCCGCCCGTCACACCCCGAGAGTTTGTAACCCCCGAAGTCGGTGAGGTAACCT
example 2 enterococcus faecium EFA5 probiotic Properties study
2.1 study of growth characteristics and acid production characteristics of enterococcus faecium EFA5
After activated and cultured for 12h by an MRS liquid culture medium, the activated strain is inoculated into a plurality of 10mL sterile centrifuge tubes filled with 9mL MRS liquid culture medium according to the inoculation amount of 1 percent, and is subjected to static culture at 37 ℃. And taking out one piece every three hours from 0h to 24h, measuring the optical density value of the piece at the OD value of 600nm by using a specific instrument, and drawing a growth curve by taking the OD value as a vertical coordinate and the time as a horizontal coordinate. The results show that the strain grows rapidly, the strain can enter a stationary phase within 18 hours, and the growth curve is shown in figure 4.
The acid-producing capacity of the culture broth was measured by the same inoculation procedure, and the culture broth was taken out after 4h, 8h, 12h, 16h, 20h and 24h of culture, the pH of the culture broth was measured by a pH meter, two parallel samples each time were averaged, and the measured pH was used for plotting. As shown in figure 5, the EFA5 strain has strong acid production capacity, the initial pH of the culture solution is 5.7, and the pH of the culture solution is reduced to 4.2 after 24 hours of culture, which indicates that the strain has good acid production capacity, and can reduce the pH value of the intestinal tract and adjust the intestinal homeostasis.
2.2 enterococcus faecium EFA5 acid tolerance and bile salt tolerance Studies
Respectively adjusting the pH value of the MRS culture solution to 2.0,3.0 and 4.0 by using 1M HCl, sterilizing for 15min by using high-pressure steam at 121 ℃, and preserving the temperature to a proper temperature for later use; adding 0%, 0.1%, 0.3% and 0.5% (w/v) of choline into MRS liquid culture medium, shaking sufficiently to dissolve choline completely, sterilizing, and keeping the temperature to a proper temperature for use. Taking out EFA5 strain from refrigerator at-80 deg.C, activating, taking 100 μ l of the bacterium solution, inoculating to 900 μ l of MRS broth with pre-adjusted pH or added with acetylcholine, marking, culturing in incubator for 12h, and setting control group. OD values of the bacterial liquid were measured at 0h and 12h after the culture, respectively. As shown in FIG. 6, the bacterial strain has good acid resistance and bile salt resistance, the OD value of the bacterial liquid of the bacterial strain in the environment with the pH value less than or equal to 3 is lower, and the OD value of the bacterial liquid is basically the same as that of the control group in the environment with the pH value of 4 or the concentration of 0%, 0.1%, 0.3% and 0.5%. The above results show that: the isolate has certain tolerance to acid environment, and the survival rate of the isolate is hardly influenced in the high-concentration bile salt environment, which shows that the isolate has good stress resistance and can survive in the gastrointestinal tract.
2.3 enterococcus faecium EFA 5-adherent porcine small intestine epithelial cells
Enterococcus faecium (Lactobacillus reuteri) EFA5 was inoculated into MRS broth, anaerobically cultured at 37 ℃ for 12 hours, centrifuged at 4000rpm at 4 ℃ for 10min, collected, washed 2 times with sterile PBS solution, and finally resuspended in DMEM (Gibco, USA) at a concentration of 1X 107cfu/mL. The porcine small intestine epithelial cells IPEC-J2 preserved in a laboratory are recovered and then subcultured, the small intestine epithelial cells IPEC-J2 in the logarithmic phase are taken for trypsinization, and the cell concentration is adjusted to about 1 multiplied by 105/mL by a DMEM medium. Placing cell slide in 6-well plate, inoculating cells into 6-well plate, inoculating 2mL per well, inoculating 5% (v/v) CO at 37 deg.C 2 Culturing overnight in the incubator, removing the culture medium after the cell slide adheres to the wall, and washing for 2 times by using PBS solution. Then 1mL of the above DMEM-resuspended EFA5 bacterial solution was added to each well, covered with a 6-well plate lid and shaken gently, placed at 37 ℃ in 5% (v/v) CO 2 Culturing for 2h in the incubator, taking out 6-well plate, discarding culture medium, washing with sterilized PBS solution for 5 times, and removing non-adhered bacteria. Then fixed with 4% paraformaldehyde overnight, stained with 0.5% crystal violet, and observed under an oil microscope for enterococcus faecium EFA5 adhering to IPEC-J2 cells. Randomly selecting the visual fields under the oil lens, wherein the visual fields are finally uniformly distributed, calculating the adhesion quantity of the lactic acid bacteria on the surfaces of all IPEC-J2 cells in each visual field, calculating an average value to represent the adhesion capacity of the strain, and taking a picture by using imaging software matched with a computer, wherein the result shows that the strain EFA5 has stronger adhesion performance to the IPEC-J2, as shown in figure 7. Calculated, an average of 8.75 bacteria were adhered to each cell. The above results show that the strain is applied to the small intestine of pigsThe skin cells have good adhesion capability and have the potential of being planted in the intestinal tracts of pigs.
Example 3 evaluation of enterococcus faecium EFA5 against porcine epidemic diarrhea Virus
3.1 cell culture
Vero cells were cultured in DMEM (Gibco, USA) containing 10% FBS (Gibco, USA), passaged when they grew into adherent monolayer cells, and digested with trypsin at 0.25% for about 1 min. The method comprises the following specific steps: discarding an old culture solution of adherent cells, washing twice by using a PBS solution, and removing a residual old culture medium; adding 1mL of digestive juice (0.25% pancreatin) into the flask, gently shaking the flask to allow the digestive juice to flow over all cell surfaces; under microscope observation, when the cell retraction process becomes round or the intercellular space increases, the digestion is stopped immediately (the digestion solution is poured off, a small amount of fresh culture solution containing serum is added, and the digestion is stopped); sucking the culture solution in the bottle by using a pipette, repeatedly blowing and beating the digested cells to enable the digested cells to be detached from the wall and dispersed to form cell suspension; subpackaging the cell suspension into new culture bottles, and supplementing a certain amount of fresh culture solution containing serum to make the total volume reach 5ml; gently shaking to make cells uniformly distributed, covering the bottle cap, and placing back to the cell incubator for culture. The morphology of normal Vero cells is shown in FIG. 8, and it can be seen that the cells are uniformly distributed, compact in density, clear in boundary and good in state.
3.2PEDV Virus propagation and titer determination
(1) Propagation of viruses
Inoculating the digested Vero cells into a T25 cell culture flask, incubating at 37 deg.C and 5% in CO2 incubator, and performing detoxification until the cells grow into a monolayer. Mixing 50 μ l of PEDV virus solution (JS 2013) preserved at-80 deg.C with 1ml of serum-free virus inoculation culture medium (10 ug EDTA-free pancreatin per ml DMEM), inoculating into a culture bottle with a single-layer Vero cell, incubating at 37 deg.C and 5% CO2 constant temperature culture box, supplementing 4ml virus inoculation culture medium after 1h, and culturing at 37 deg.C and 5% CO2 constant temperature culture box for 24-48h; the cell state was observed every day, and virus cell proliferation solution was harvested when lesions appeared in more than 80% of the cells. Repeatedly freezing and thawing the virus cell proliferation solution for 3 times, centrifuging at 4000rpm for 10min, collecting supernatant virus solution, and storing at-80 deg.C for use. PEDV infected Vero cells produced lesions as shown in FIG. 9, the cell boundaries were blurred in the lesion area, the cells fused and crushed, and the cell debris floated on the culture medium.
(2) Viral titer determination
Calculation of Virus Titers (TCID) in PEDV Virus solution Using Reed-Muench method 50 And/ml) comprises the following specific steps:
inoculating the digested Vero cells to a 96-well plate, incubating at 37 ℃ and 5% CO 2 Culturing in a constant temperature incubator until monolayer cells grow out; PEDV virus solution was serially diluted 10-fold to 10-fold with inoculation medium in 2ml sterile centrifuge tubes -6 (ii) a Inoculating diluted virus solution into 96-well plate with single-layer Vero cells, inoculating one vertical row of each dilution for 8 wells, inoculating 100ul virus amount into each well, inoculating virus-free inoculation culture medium in 7 th and 8 th vertical rows as control, and culturing at 37 deg.C and 5% CO 2 Incubation in a constant temperature incubator at 37 ℃ and 5% CO 2 Culturing in a constant temperature incubator for 2-5 days; cytopathic (CPE) status was observed and recorded daily and TCID of PEDV virus fluid was calculated according to the Reed-Muerch method 50 。
As a result, the TCID of the virus was found 50 Is 10 -4.33 /0.1ml。
3.3 preparation of enterococcus faecium EFA51 fermentation supernatant
Activating enterococcus faecium EFA5, inoculating into MRS broth, standing at 37 deg.C for 10 h, centrifuging at 10000r/min for 5min, adjusting supernatant pH to 7.0 with NaOH, filtering with 0.22 μm filter, and storing at-20 deg.C in refrigerator.
3.4 cytotoxicity assay of enterococcus faecium EFA51 fermentation supernatant
The cell suspension was seeded in a 96-well plate and cultured until a monolayer of cells grew out. Taking the fermentation supernatant of enterococcus faecium EFA51 to perform gradient dilution by 2 times, and selecting different gradient dilutions of 1, 1/2, 1/4, 1/8, 1/16 and 1/32. Treatment groups were added 100ul of fermentation supernatants at different dilutions per well, 5% CO at 37 ℃ in 5 replicates per dilution 2 Incubating in an incubator, and simultaneously setting a cell control and a virus control;observing cytopathic condition every day, and measuring cell activity and cytotoxicity by CCK-8 method when cell CPE of virus control group reaches above 80 = (control group OD) 450 Treatment group OD 450 ) Control group OD 450 X 100%. As shown in FIG. 10, the fermentation supernatant stock was highly toxic to the cells, while the 1/4 dilution of the fermentation supernatant was not toxic to the cells.
3.5CCK8 method for indirectly detecting inhibition rate of enterococcus faecium EFA5 fermentation supernatant on PEDV
The cell suspension was seeded in a 96-well plate and cultured until a monolayer of cells grew out. Inoculating enterococcus faecium EFA5 fermentation supernatant into 96-well plate cells, culturing for 90min, washing with DMEM, infecting the cells with PEDV with MOI =0.01, placing in an incubator for adsorption for 90min, washing, adding cell maintenance liquid, and continuing culturing. A virus control group and a normal cell control group are simultaneously set. Virus control: PEDV with MOI =0.01 was used to infect Vero cells, which were placed in an incubator for 90min and washed with PBS, and cell maintenance medium was added to continue the culture. Viral inhibition rate = (probiotic treated group OD) 450 Viral control group OD 450 ) V (cell control OD) 450 Viral control group OD 450 ) X 100%. As shown in FIG. 11, the inhibition rate of the enterococcus faecium EFA5 fermentation supernatant on PEDV at the cell level can reach 60%, and the inhibition effect on viruses is gradually weakened along with the increase of the dilution degree in a dose-dependent manner.
3.6 Effect of enterococcus faecium EFA5 fermentation supernatants on PEDV titre
The experiment is divided into a treatment group and a control group, and the specific operation is as follows:
treatment group: spreading the digested Vero cells in a 96-well plate, incubating at 37 deg.C, 5% 2 Culturing in a constant temperature incubator until monolayer cells grow out; discarding the old culture medium, washing with PBS, adding 100 μ l of bacterial metabolite per well at 37 deg.C, 5% CO2, incubating for 90min; continuously diluting PEDV virus solution 10 times to 10-6 with DMEM, inoculating one vertical row at each dilution, inoculating 100ul virus amount in each well, inoculating nontoxic DMEM culture medium in 7 th and 8 th vertical rows as control, and determining CO content at 37 deg.C and 5% 2 Incubating for 1h in a constant-temperature incubator; carefully aspirate the virus incubation and DMEM media with a pipette, adding 10 per well0ul DMEM cell maintenance solution, 37 ℃, 5% 2 Culturing for about 72 hours in a constant temperature incubator.
Control group: the bacterial metabolites were replaced with DMEM, 100. Mu.l per well, incubated for 90min, and the rest of the treatment was the same.
Cytopathic (CPE) status was observed and recorded daily until no new lesions were produced and the TCID50 of the PEDV virus fluid was calculated according to the Reed-Muerch method.
As a result, as shown in fig. 12, the EFA5 fermentation supernatant pretreatment group reduced the virus titer very significantly (about 10-fold) compared to the control group.
3.7 Effect on viral M Gene copy number
(1) Sample preparation
Vero cell suspension was seeded in 12-well plates and cultured until a monolayer of cells grew out. Inoculating 1ml of probiotic metabolite to cells, co-culturing at 37 ℃ for 90min in a cell culture box, washing with PBS, infecting the cells with PEDV (PEDV) with MOI =0.01, adsorbing for 1h in the culture box, washing with PBS, adding a cell maintenance solution, and continuing culturing. And simultaneously, a virus control group is set. Each set was 3 replicates. And (3) when the cytopathic effect of the virus control group reaches about 80 percent, collecting the virus, putting the 12-hole cell culture plate into a refrigerator at minus 80 ℃ for repeated freeze thawing three times, and centrifugally collecting supernatant to obtain the sample to be detected.
(2) RT-qPCR method for detecting copy number of PEDV M gene in each sample
I. Extraction of Total RNA from viral supernatants
The total RNA of the virus liquid is extracted by an RNA fast200RNA kit (Dieckmann, china), and is stored in a refrigerator at the temperature of 80 ℃ below zero for later use.
Reverse transcription of
The total RNA obtained was reverse transcribed using the HiScript II 1st Strand cDNA Synthesis Kit (Vazyme, china) in the following system:
a. genomic DNA removal (16 μ l system):
reaction procedures are as follows: 42 ℃ for 2min.
b. First strand cDNA Synthesis reaction solution (20. Mu.l system) was prepared:
reaction procedure: 15min at 50 ℃; at 85 ℃ for 2min.
Real-time quantification of PEDV M Gene Using qPCR
Real-time fluorescence quantification of reverse transcription products was performed using AceQ Universal SYBR qPCR Master Mix kit (Vazyme, CHINA) in the following reaction system:
reaction procedure: 5min at 95 ℃; 10s at 95 ℃, 30s at 60 ℃, and 40 cycles;
the detection results are shown in fig. 13, and after 12h and 24h of virus infection, the copy numbers of the virus M genes of the probiotic fermentation supernatant pretreatment group are both significantly lower than those of the control group. Taking 24h after infection as an example, the copy number of the virus gene in the control group is 4.8 multiplied by 10 8 While the EDA5 fermentation supernatant pretreatment group had a viral gene copy number of 1.1X 10 8 . The results show that the virus content in Vero cells can be obviously reduced by the enterococcus faecium EFA5 fermentation supernatant, so that the enterococcus faecium EFA5 screened by the method can effectively inhibit the replication of porcine epidemic diarrhea viruses and has strong antiviral capacity.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (8)
1. An Enterococcus faecium (Enterococcus faecium) EFA5 with the function of resisting porcine epidemic diarrhea virus, and the preservation number is as follows: GDMCC NO.62904 is deposited at the microbial cultures Collection of Guangdong province, and the deposition address is the institute of microbiology, guangdong province academy of sciences, guangzhou, guangdong province.
2. The enterococcus faecium EFA5 having the function of resisting the porcine epidemic diarrhea virus according to claim 1, wherein the enterococcus faecium EFA5 is separated from the feces of healthy Luchuan sows and weaned piglets.
3. The enterococcus faecium EFA5 having the anti-porcine epidemic diarrhea virus function of claim 1, wherein the enterococcus faecium EFA5 has an inhibitory effect on porcine epidemic diarrhea virus.
4. A feed or feed additive comprising enterococcus faecium EFA5 and/or a fermentation product thereof according to any one of claims 1 to 3.
5. Use of enterococcus faecium EFA5 according to any one of claims 1 to 3 for the preparation of a medicament against porcine epidemic diarrhea virus.
6. The use of enterococcus faecium EFA5 in the preparation of a medicament for the treatment of porcine epidemic diarrhea virus according to claim 5, wherein said medicament comprises enterococcus faecium EFA5 and/or a fermentation product thereof.
7. Use according to claim 5, wherein the pharmaceutical dosage form is a tablet, capsule, powder, pill, granule or solution.
8. The use of claim 5, wherein the medicament comprises enterococcus faecium EFA5 and/or a fermentation product thereof, and a pharmaceutically acceptable excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211474092.8A CN115975870B (en) | 2022-11-23 | 2022-11-23 | Enterococcus faecium with porcine epidemic diarrhea virus resisting function and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211474092.8A CN115975870B (en) | 2022-11-23 | 2022-11-23 | Enterococcus faecium with porcine epidemic diarrhea virus resisting function and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115975870A true CN115975870A (en) | 2023-04-18 |
| CN115975870B CN115975870B (en) | 2024-08-06 |
Family
ID=85961810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211474092.8A Active CN115975870B (en) | 2022-11-23 | 2022-11-23 | Enterococcus faecium with porcine epidemic diarrhea virus resisting function and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115975870B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117603842A (en) * | 2023-10-17 | 2024-02-27 | 健合香港有限公司 | Composite microbial agent and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050023475A (en) * | 2003-08-27 | 2005-03-10 | 주식회사 프로바이오닉 | Acid tolerant probiotic Enterococcus faecalis Probio-056 that can suppresses the growth of pathogenic microorganisms and PED coronavirus |
| CN107828706A (en) * | 2017-10-18 | 2018-03-23 | 东北农业大学 | A kind of eGFP is marked, anti-swine infectious enterogastritis and the restructuring VREF vaccine strain of pig epidemic diarrhea and its application |
| CN107893111A (en) * | 2017-12-29 | 2018-04-10 | 武汉轻工大学 | A kind of screening technique of the feeding probiotics of anti-piglet epidemic diarrhea |
| CN113080309A (en) * | 2021-04-27 | 2021-07-09 | 山东蔚蓝生物科技有限公司 | Bacillus subtilis with antibacterial and antiviral functions and application thereof |
| CN115444876A (en) * | 2022-09-07 | 2022-12-09 | 华中农业大学 | Fermented traditional Chinese medicine preparation for resisting porcine epidemic diarrhea virus and preparation method thereof |
| CN115786175A (en) * | 2022-09-30 | 2023-03-14 | 广东省农业科学院动物卫生研究所 | Lactobacillus mucosae and application thereof |
| CN116042483A (en) * | 2023-02-17 | 2023-05-02 | 佛山科学技术学院 | Enterococcus faecium FSUH-1 capable of producing gamma-aminobutyric acid and application thereof |
-
2022
- 2022-11-23 CN CN202211474092.8A patent/CN115975870B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050023475A (en) * | 2003-08-27 | 2005-03-10 | 주식회사 프로바이오닉 | Acid tolerant probiotic Enterococcus faecalis Probio-056 that can suppresses the growth of pathogenic microorganisms and PED coronavirus |
| CN107828706A (en) * | 2017-10-18 | 2018-03-23 | 东北农业大学 | A kind of eGFP is marked, anti-swine infectious enterogastritis and the restructuring VREF vaccine strain of pig epidemic diarrhea and its application |
| CN107893111A (en) * | 2017-12-29 | 2018-04-10 | 武汉轻工大学 | A kind of screening technique of the feeding probiotics of anti-piglet epidemic diarrhea |
| CN113080309A (en) * | 2021-04-27 | 2021-07-09 | 山东蔚蓝生物科技有限公司 | Bacillus subtilis with antibacterial and antiviral functions and application thereof |
| CN115444876A (en) * | 2022-09-07 | 2022-12-09 | 华中农业大学 | Fermented traditional Chinese medicine preparation for resisting porcine epidemic diarrhea virus and preparation method thereof |
| CN115786175A (en) * | 2022-09-30 | 2023-03-14 | 广东省农业科学院动物卫生研究所 | Lactobacillus mucosae and application thereof |
| CN116042483A (en) * | 2023-02-17 | 2023-05-02 | 佛山科学技术学院 | Enterococcus faecium FSUH-1 capable of producing gamma-aminobutyric acid and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| SIRICHOKCHATCHAWAN W等: "Protective Effects of Cell-Free Supernatant and Live Lactic Acid Bacteria Isolated from Thai Pigs Against a Pandemic Strain of Porcine Epidemic Diarrhea Virus", PROBIOTICS ANTIMICROB PROTEINS, vol. 10, no. 2, 30 June 2018 (2018-06-30), pages 383 - 390, XP036515147, DOI: 10.1007/s12602-017-9281-y * |
| WEIDONG CHAI 等: "Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus", ARCH VIROL, vol. 158, no. 4, 28 November 2012 (2012-11-28), pages 799 - 807 * |
| 张敏: "乳酸菌培养上清对猪流行性腹泻病毒体外增殖的影响和机理研究[D].武汉轻工大学", 中国优秀硕士学位论文全文数据库基础科学辑, no. 02, 15 February 2023 (2023-02-15), pages 006 - 2170 * |
| 朱娜等: "湖南健康猪源与流行性腹泻病猪肠球菌毒力基因检测分析", 中国预防兽医学报, vol. 39, 31 December 2017 (2017-12-31), pages 196 - 200 * |
| 王添翔: "抑制PEDV黏附的猪源乳杆菌的分离鉴定及其S层蛋白在抑制PEDV黏附中的作用", 中国优秀硕士学位论文全文数据库基础科学辑, no. 07, 15 July 2019 (2019-07-15), pages 006 - 508 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117603842A (en) * | 2023-10-17 | 2024-02-27 | 健合香港有限公司 | Composite microbial agent and application thereof |
| CN117603842B (en) * | 2023-10-17 | 2024-07-05 | 健合香港有限公司 | Composite microbial agent and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115975870B (en) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113980878B (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof | |
| CN110964653B (en) | Lactobacillus paracasei ET-22 capable of adjusting intestinal flora balance | |
| CN113604384B (en) | Lactobacillus rhamnosus and application thereof | |
| CN107338198B (en) | Lactobacillus plantarum and application thereof | |
| CN109749957B (en) | Preparation and application of lactobacillus gasseri preparation with aquatic pathogenic bacteria antagonistic property | |
| CN108743624B (en) | Application of lactobacillus plantarum ZN-3 in preparation of medicine for treating or preventing porcine epidemic diarrhea virus infection | |
| CN113249255B (en) | Bacillus subtilis for preventing and controlling enteritis of poultry and application thereof | |
| CN109735471B (en) | Microbacterium and application thereof as probiotic in aquatic products | |
| CN109182164B (en) | Lactobacillus reuteri strain and application thereof in bee breeding process | |
| CN113293118B (en) | Lactobacillus rhamnosus LR3001 and application thereof | |
| CN112375712A (en) | Lactococcus lactis and application thereof | |
| CN113122466A (en) | Enterococcus faecalis and application thereof | |
| CN118374422B (en) | Lactobacillus reuteri LR1218 and application thereof | |
| CN115975870B (en) | Enterococcus faecium with porcine epidemic diarrhea virus resisting function and application thereof | |
| CN113512516B (en) | Cooperative swine-origin lactobacillus mucosae and application thereof | |
| CN113151096B (en) | Bacillus subtilis for resisting novel reovirus and application thereof | |
| CN105062914B (en) | Screening and application of clostridium butyricum for adjusting balance of intestinal flora of livestock and poultry | |
| Akhlaghi et al. | Development of a novel and specialized cultivation method for isolating Helicobacter pullorum from chicken meat | |
| CN108486004B (en) | Lactobacillus for inhibiting PEDV adhesion | |
| CN107254424B (en) | Novel liquid composite microecological preparation for livestock and poultry and preparation method thereof | |
| CN115873081A (en) | Lactein and application thereof in prevention and control of bacterial infection of pets | |
| CN110079477B (en) | Lactobacillus plantarum for preventing and treating pullorum disease salmonella, preparation and application thereof | |
| CN114381390A (en) | Bifidobacterium longum ME-875 and application thereof | |
| CN113508907A (en) | Application of heat-resistant lactobacillus fermentum in preparation of defecation promoting food or medicine | |
| CN111363706A (en) | Ecliptae herba endophytic bacteria, eclipta alba composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Xianxi Campus, No. 33, Guangyun Road, Shishan Town, Nanhai District, Foshan City, Guangdong Province, 528200 Patentee after: Foshan University Country or region after: China Address before: Xianxi Campus, No. 33, Guangyun Road, Shishan Town, Nanhai District, Foshan City, Guangdong Province, 528200 Patentee before: FOSHAN University Country or region before: China |